Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Alefan, Qais; Saadeh, Alaa; Yaghan, Rami J.

doi:10.2217/bmt-2019-0014

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our estimates are aligned with the outcomes of several studies conducted in other countries including the US, Canada, Belgium, the United Kingdom (UK), Italy, and Jordan, which showed a strong correlation between disease stage and total cost of treatment; patients with more advanced disease require more intensive treatment and use more healthcare resources than patients with early-stage disease [ 9 , 10 , 19 , 20 , 21 ]. The availability of costing data per cancer stage is crucial for assessing the value of potential breast cancer treatment and prevention programs.…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

et al. 2021

View full text Add to dashboard Cite

Globally, breast cancer management is associated with a heavy economic burden, but its impact in Saudi Arabia has not been fully quantified. The aim of this study was to estimate the economic burden of breast cancer management at various disease stages, in Saudi Arabia, from a payer perspective. We conducted a retrospective, multicenter cost of illness study in two governmental healthcare centers from January to December 2018, using the data of 300 patients at different breast cancer stages. A micro-costing, bottom-up method was used, and descriptive and inferential statistics were analyzed. The total estimated cost for treating breast cancer during the study period was $13.345 million USD, with the average cost per patient ranging from $14,249 USD in stage I to $81,489 USD in stage IV (p < 0.001). Medication cost was the main driver of total healthcare spending, followed by hospitalization and diagnostic tests. The cost of targeted therapy drugs represented 67% of the total medication costs, mostly driven by trastuzumab-based regimens. The economic burden of breast cancer management in Saudi Arabia is substantial and increases significantly with disease advancement. Early detection screening programs, evaluating the value of highly expensive interventions, and considering biosimilars, may contribute toward cost savings.

show abstract

Section: Discussionsupporting

confidence: 81%

“…It is well documented that breast cancer imposes a significant economic burden on healthcare systems and societies, especially during the first year following diagnosis. However, breast cancer also has a substantial long-term economic impact, as breast cancer survivors require continuous inpatient and outpatient care [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite significant advances in breast cancer management in recent years, the incidence and mortality rates of this disease are still increasing in developed and developing countries; this has led to a significant increase in global patient-related healthcare costs [ 16 ] and has imposed a great economic burden on health care systems and communities [ 35 ]. The aim of the present study was to determine the economic burden of breast cancer in the patients referred to medical centers in Fars province in southern Iran in 2021.…”

Section: Discussionmentioning

confidence: 99%

Economic burden of breast cancer: a case of Southern Iran

Jalali,

Keshavarz,

Seif

et al. 2023

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Background Breast cancer is one of the main causes of death from cancer around the world, imposing a significant economic burden on the families and healthcare system. The present study aimed at determining the economic burden of breast cancer in the patients referred to the medical centers in Fars province in southern Iran in 2021. Methods This cross-sectional study is a partial economic evaluation and a cost-of-illness study with a bottom-up and prevalence-based approach, conducted in Fars province in southern Iran in 2021 from the societal perspective. A total of 230 patients were randomly included in the study, and a researcher-made data collection form was used to collect the required data. The data on direct medical costs were collected using the information on patients’ medical and financial records. On the other hand, the data on direct non-medical and indirect costs were obtained using self-reports by the patients or their companions. The Excel 2016 software was used to analyze the collected data. Results The results showed that the annual cost of each breast cancer patient in the studied sample was 11,979.09 USD in 2021. Direct medical costs accounted for the largest share of costs (70.69%, among which the cost of radiotherapy was the highest one. The economic burden of the disease in the country was estimated at 193,090,952 USD. Conclusions In general, due to the high prevalence of breast cancer and the chronicity of this disease, its medical costs can impose a heavy economic burden on society, the health system, the insurance system, and patients. Thus, in order to reduce the costs, the following suggestions can be offered: the use of advanced radiotherapy techniques, increasing the insurance coverage of required services, establishing low-cost accommodation centers near medical centers for the patients and their companions, providing specialized medical services for the patients in towns, using the Internet and virtual space to follow up the treatment of the patients, and carrying out free screening programs and tests for faster diagnosis of the infected patients and susceptible or exposed people.

show abstract

“…For instance, in the Kingdom of Jordan, the incidence and mortality rates of cancer are rapidly increasing; between 2000 and 2013, the average crude cancer incidence rate in Jordan was 82.8/100 000 population,5 while in 2016, the crude incidence rate increased to 87.2/100 000 population 6. In addition, the treatment costs of some cancer types, such as breast cancer, surged significantly in the late disease stages in Jordan 7 8…”

Section: Introductionmentioning

confidence: 99%

Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers

et al. 2023

View full text Add to dashboard Cite

ObjectivesLate presentation or diagnosis of cancer results in a poor clinical prognosis, negatively affects treatment and subsequently lowers one’s chances of survival. This study aimed to identify the factors associated with late lung and colorectal cancer presentation and diagnosis in Jordan.DesignThis correlational cross-sectional study was based on face-to-face interviews and medical chart reviews from a cancer registry database. A structured questionnaire based on a review of the literature was used.Setting and participantsThe study participants were a representative sample of adult patients with colorectal or lung cancer who visited the outpatient clinics at King Hussein Cancer Center in Amman, Jordan, between January 2019 and December 2020, to get their first medical consultation.Results382 study participants were surveyed, with a response rate of 82.3%. Of these, 162 (42.2%) reported a late presentation and 92 (24.1%) reported a late diagnosis of cancer. The results of backward multivariate logistic regression analyses showed that female gender and not seeking a medical advice when feeling ill combined was associated with an almost three times increased likelihood of reporting a late presentation with cancer (adjusted OR 2.97, 95% CI 1.19 to 7.43). Not having health insurance and not seeking medical advice combined was also associated with late presentation (2.5, 95% CI 1.02 to 6.12). For lung cancer, Jordanians living in rural areas were 9.29 (95% CI 2.46 to 35.1) times more likely to report late diagnosis. Jordanians who did not screen for cancer in the past were 7.02 (95% CI 1.69 to 29.18) times more likely to report late diagnosis. For colorectal cancer, those having no previous knowledge about cancers or screening programmes had increased odds of reporting late diagnosis (2.30, 95% CI 1.06 to 4.97).ConclusionsThis study highlights important factors associated with the late presentation and diagnosis of colorectal and lung cancers in Jordan. Investing in national screening and early detection programmes as well as public outreach and awareness campaigns will have a significant impact on early detection to improve treatment outcomes.

show abstract

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Cited by 8 publications

References 31 publications

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

Economic burden of breast cancer: a case of Southern Iran

Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers

Contact Info

Product

Resources

About